Trimethyl-(2-octadecanoyl-3-oxo-2-phosphonooxydocosa-7,10,13,16-tetraenyl)azanium

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Trimethyl-(2-octadecanoyl-3-oxo-2-phosphonooxydocosa-7,10,13,16-tetraenyl)azanium
• 英文别名: trimethyl-(2-octadecanoyl-3-oxo-2-phosphonooxydocosa-7,10,13,16-tetraenyl)azanium
• 化学式: C43H79NO6P+
• 分子量: 737.1
• InChiKey: ACFNTAWASHFGPI-UHFFFAOYSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  12.9
• 重原子数：
  51
• 可旋转键数：
  36
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• NOVEL LIPID MIXTURES FOR SYNTHETIC SURFACTANTS
  申请人：CHIESI FARMACEUTICI S.p.A.

  公开号：EP1628634A1

  公开（公告）日：2006-03-01
• RECONSTITUTED PULMONARY SURFACTANTS
  申请人：Chiesi Farmaceutici S.p.A.

  公开号：EP2922868A1

  公开（公告）日：2015-09-30
• SURFACTANT FORMULATIONS FOR INHALATION
  申请人：Civitas Therapeutics, Inc.

  公开号：EP3474832A1

  公开（公告）日：2019-05-01
• Novel Lipid Mixtures For Synthetic Surfactants
  申请人：Johansson Jan

  公开号：US20080045449A1

  公开（公告）日：2008-02-21

  The present invention provides novel lipid mixtures for synthetic surfactants. In particular, the invention provides a specific lipid mixture containing a specific amount of polyunsaturated phospholipids to be used for the preparation of synthetic surfactants. Said surfactants and pharmaceutical compositions thereof are useful for the treatment of surfactant deficiencies like respiratory distress syndrome (RDS).
• Surfactant Formulations for Inhalation
  申请人：Civitas Therapeutics, Inc.

  公开号：US20210169794A1

  公开（公告）日：2021-06-10

  The present invention is directed respirable, dry powder particle formulations of lung surfactants that optionally comprise surfactant proteins and that are formulated for delivery to the pulmonary system via inhalation.